GenSight Biologics S.A. (0RIM.L)
| Previous close | 0.3180 |
| Open | 0.3210 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.3210 - 0.3210 |
| 52-week range | 0.3210 - 2.5300 |
| Volume | |
| Avg. volume | 2,025 |
| Market cap | 9.133M |
| Beta (5Y monthly) | 2.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update
PARIS, July 23, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of June 30, 2024, and provided a business update.
- Business Wire
GenSight Biologics Launches Newsletter for Retail Investors
PARIS, July 11, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today published the first issue of a company newsletter aimed at retail investors in France. The quarterly newsletter will be published in French and will be available via the company’s website and by subscription.
- Business Wire
GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates
PARIS, June 20, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the renegotiation of certain financial obligations, securing its financial position and improving short-term flexibility. The Company also provided operational updates.
